Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, the poor dividend history, and the high PEmg and PB ratios.
Alexion Pharmaceuticals Inc. is not suitable for the more conservative Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned with the insufficient earnings growth or stability over the last ten years, the lack of dividends, and the high PEmg and PB ratios.
We evaluated 47 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Alexion Pharmaceuticals is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the lack of dividends, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios, while the Enterprising Investor is only concerned by the lack of dividends.
We evaluated 58 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Alexion Pharmaceuticals Inc. is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the insufficient earnings growth or stability over the last ten years, the lack of dividends and the high PEmg and PB ratios.
We evaluated 14 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Alexion Pharmaceuticals qualifies for the Enterprising Investor but not the Defensive Investor. The Defensive Investor has numerous concerns including the lack of earnings stability or growth over the last ten years, the lack of dividend payments and the high PEmg and PB ratios.